FGEN241220P1000
- 0.65
- 0.000.00%
FibroGen Newsroom
FibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside Potential
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
Sell Rating on FibroGen Amid Skepticism Over Clinical Outcomes and Drug Efficacy
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2
FibroGen Analyst Ratings
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29
Goldman Sachs Adjusts FibroGen's Price Target to $2 From $16, Keeps Sell Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Option Care Health (OPCH) and FibroGen (FGEN)
FibroGen (FGEN) Receives a Sell From Goldman Sachs
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28
FibroGen (FGEN) Receives a Sell From Goldman Sachs
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tonix Pharma (TNXP), ANI Pharmaceuticals (ANIP) and FibroGen (FGEN)
Goldman Sachs Remains a Sell on FibroGen (FGEN)
Goldman Sachs Sticks to Their Sell Rating for FibroGen (FGEN)
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating
Cowen & Co. Maintains Market Perform on FibroGen, Raises Price Target to $25
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO), FibroGen (FGEN) and Disc Medicine (IRON)
Goldman Sachs Maintains Sell on FibroGen, Raises Price Target to $16
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating